BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 69,743 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $85.69, for a total value of $5,976,277.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Monday, November 21st, Jean Jacques Bienaime sold 69,744 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $87.56, for a total value of $6,106,784.64.
  • On Monday, November 7th, Jean Jacques Bienaime sold 70,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.52, for a total value of $5,776,400.00.
  • On Tuesday, November 8th, Jean Jacques Bienaime sold 140,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.67, for a total value of $11,573,800.00.
  • On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.30, for a total value of $9,756,000.00.
  • On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.39, for a total value of $3,516,193.74.
  • On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $86.96, for a total value of $5,576,310.00.
  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.65, for a total value of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.34, for a total value of $13,096,665.12.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) remained flat at $88.10 on Thursday. 1,299,103 shares of the stock were exchanged. BioMarin Pharmaceutical Inc. has a 52 week low of $62.12 and a 52 week high of $107.56. The firm’s market cap is $15.15 billion. The firm’s 50-day moving average price is $86.66 and its 200 day moving average price is $89.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.13. The company had revenue of $279.90 million for the quarter, compared to analyst estimates of $289.70 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. BioMarin Pharmaceutical’s quarterly revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.60) earnings per share. On average, analysts predict that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Several analysts have recently commented on the company. Vetr upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $91.77 price objective for the company in a report on Monday. Credit Suisse Group AG reiterated a “buy” rating and set a $111.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday, November 7th. Piper Jaffray Cos. lowered BioMarin Pharmaceutical from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $105.00 to $84.00 in a report on Monday, November 7th. They noted that the move was a valuation call. Deutsche Bank AG assumed coverage on BioMarin Pharmaceutical in a report on Thursday, November 3rd. They set a “buy” rating and a $106.00 price objective for the company. Finally, Zacks Investment Research lowered BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 1st. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. BioMarin Pharmaceutical has an average rating of “Buy” and an average target price of $115.24.

A number of hedge funds and other institutional investors have recently bought and sold shares of BMRN. Cornerstone Advisors Inc. raised its position in BioMarin Pharmaceutical by 22.0% in the third quarter. Cornerstone Advisors Inc. now owns 1,159 shares of the company’s stock worth $107,000 after buying an additional 209 shares in the last quarter. Rockefeller Financial Services Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth approximately $111,000. Independent Portfolio Consultants Inc. acquired a new position in BioMarin Pharmaceutical during the third quarter worth approximately $121,000. Toronto Dominion Bank raised its position in BioMarin Pharmaceutical by 57.8% in the third quarter. Toronto Dominion Bank now owns 1,401 shares of the company’s stock worth $130,000 after buying an additional 513 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth approximately $140,000. Institutional investors own 93.68% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sells-69743-shares.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.